A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (NCT04634552)
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
Who can join: Review the eligibility criteria below.
Location: University of Alabama Birmingham — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (78 Sites)
Showing the first 25 of 78 sites.
- University of Alabama Birmingham — Birmingham, Alabama
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- City of Hope — Duarte, California
- Memorial Healthcare System — Hollywood, Florida
- Emory University Winship Cancer Institute — Atlanta, Georgia
- University of Chicago — Chicago, Illinois
- Norton Cancer Institute — Louisville, Kentucky
- University of Michigan Health System — Ann Arbor, Michigan
- Washington University School Of Medicine — St Louis, Missouri
- NYU Langone Health — New York, New York
- Mount Sinai Medical Center — New York, New York
- University of Rochester Medical Center — Rochester, New York
- Providence Portland Medical Center — Portland, Oregon
- Tennessee Oncology — Nashville, Tennessee
- UZ Antwerpen — Edegem,
- UZ Leuven — Leuven,
- CHU de Liège - Domaine Universitaire du Sart Tilman — Liège,
- UCL - Saint Luc — Woluwe-Saint-Lambert,
- Peking University Third Hospital — Beijing,
- Sun Yat Sen University Cancer Center — Guangzhou,
- The 1st Affiliated Hospital Of Medical College Zhejiang University 1 — Hangzhou,
- The 1St Affiliated Hospital of Medical College Zhejiang University — Hangzhou,
- First Affiliated Hospital SooChow University — Suzhou,
- Institute of Hematology & Blood Disease Hospital Chinese Academy of Medical Science — Tianjin,
- The Second Affiliated Hospital of Xi'an Jiaotong University — Xi'an,
📞 Contact the Study Coordinator
Phone: (844) 434-4210
Email: Participate-In-This-Study1@its.jnj.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hematological Malignancies
- A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma — Birmingham, Alabama
- Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma — Birmingham, Alabama
- Feasibility of the Use of Weighted Blankets to Improve Sleep Among Patients With Hematological Malignancies — Houston, Texas
- Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma — Duarte, California
- Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies — Houston, Texas
Explore by condition: All Hematological Malignancies clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.